Skip to Main Content

Author Details

Amanda L Christie
Dana-Farber Cancer Institute
2010
36
30
PMIDPaper TitleJournal TitlePublished Year
30498064Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.Blood2019
31748664Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models.Sci Rep2019
31437130DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.J Clin Invest2019
31040105Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.Cancer Discov2019
29789628Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.Nat Commun2018
29567799Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.Blood2018
28881711Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.Oncotarget2017
28967922Inhibition of USP10 induces degradation of oncogenic FLT3.Nat Chem Biol2017
29045844A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas.Cell Rep2017
29092942PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.Cancer Res2017
26202935Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.Leukemia2016
27742706HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.Blood2016
27479034The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.Cancer Cell2016
27070704The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.Cancer Cell2016
26773040Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.Blood2016
24791855Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.Leukemia2015
26289068Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.Clin Cancer Res2015
26416749Mediator kinase inhibition further activates super-enhancer-associated genes in AML.Nature2015
26175414Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.Cancer Cell2015
25833960Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.Blood2015
25485910Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.Nat Med2015
24569262Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Blood2014
25228590Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.Oncotarget2014
22847027Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.Leukemia2013
23536552High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.Cancer Res2013
23373539KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.Br J Haematol2013
22182920Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.Leukemia2012
23264850The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.Genes Cancer2012
23079655The requirement for cyclin D function in tumor maintenance.Cancer Cell2012
22683780Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.Nat Med2012
22469781Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.Leukemia2012
22271575Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.J Exp Med2012
21447744Differentiation of NUT midline carcinoma by epigenomic reprogramming.Cancer Res2011
21368833SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.Nature2011
20871596Selective inhibition of BET bromodomains.Nature2010
20844561Smac mimetics: implications for enhancement of targeted therapies in leukemia.Leukemia2010
  • 1 - 36 of 36

Recommended Authors

Veronique Litalien
Walter and Eliza Hall Institute of Medical Research
Career Start Year 2016
Number of shared co-authors 0
Chelsea Mayoh
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2016
Number of shared co-authors 4
Anna Senina
Huntsman Cancer Institute, The University of Utah
Career Start Year 2013
Number of shared co-authors 2
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 2
Stuart J Blakemore
Center for Molecular Medicine Cologne (CMMC), University of Cologne
Career Start Year 2010
Number of shared co-authors 3
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 1
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Elisabeth A Lasater
University of California san francisco
Career Start Year 2008
Number of shared co-authors 1
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 4
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 7
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 8
Alexey V Danilov
City of Hope National Medical Center
Career Start Year 2005
Number of shared co-authors 4
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 4
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 13
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 8
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Phillip M Clair
Huntsman Cancer Institute, The University of Utah
Career Start Year 2001
Number of shared co-authors 2
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 2
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 4
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 2
Kathryn Evans
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year 1996
Number of shared co-authors 4
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 12
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1993
Number of shared co-authors 8
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 7
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 8
Ricky W Johnstone
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 5
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 3
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year 1987
Number of shared co-authors 5
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 16

Collaborators

David M Weinstock
Merck & Co.
Co-authored papers 16
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 10
Alex Look
Dana-Farber Cancer Institute
Co-authored papers 8
Mark A Murakami
Dana-Farber Cancer Institute
Co-authored papers 5
Aaron R Thorner
Co-authored papers 5
Nathanael S Gray
Harvard Medical School
Co-authored papers 5
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 5
Alex Kentsis
Memorial Sloan-Kettering Cancer Center
Co-authored papers 4
Giorgio Inghirami
Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Co-authored papers 4
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 3
Benjamin L Ebert
Co-authored papers 3
David P Steensma
Novartis Institutes for BioMedical Research
Co-authored papers 3
Paul Van Hummelen
Co-authored papers 3
David M Dorfman
Brigham and Women's Hospital and Harvard Medical School
Co-authored papers 3
James E Bradner
Co-authored papers 3
Myles Brown
Co-authored papers 2
Jerome Ritz
Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital
Co-authored papers 2
Casie Reed
Co-authored papers 2
Kenneth C Anderson
Dana Farber Cancer Institute
Co-authored papers 2
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Timothy A Graubert
Massachusetts General Hospital
Co-authored papers 2
Donna Neuberg
Co-authored papers 2
Mahmoud Ghandi
Co-authored papers 2
Stuart H Orkin
Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 2
Dylan J Taatjes
University of Colorado
Co-authored papers 1
Jeremy Mason
European Molecular Biology Laboratory - European Bioinformatics Institute
Co-authored papers 1
Fr??d??ric Amant
Netherlands Cancer Institute
Co-authored papers 1
Sirano Dhe-Paganon
Dana-Farber Cancer Institute
Co-authored papers 1
Giovanni Ciriello
University of Lausanne (UNIL)
Co-authored papers 1
Jun Qi
Dana-Farber Cancer Institute
Co-authored papers 1
Release 1.2